Drugs / TT301
TT301
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02942771 | Mar 2017 → Jun 2018 | — | Linda Van Eldik | Completed | No outcome recorded |
| Phase 1 | NCT01357421 | May → Jun 2011 | traumatic brain injury | OPKO Health, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05020535 | Oct 2022 → Nov 2026 expected | intracerebral hemorrhage | Johns Hopkins University | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01357421 ↗ |
| Known as | MW01-6-189WH | “This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).” NCT05020535 ↗1“MW01-6-189WH (MW189) is a novel central nervous system-penetrant small-molecule drug candidate” PMID 32255549 ↗ Apr 2020 |
| Known as | MW189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05020535 ↗ |
| Action | Inhibit | “MW189 is a novel small molecule drug candidate developed as a selective suppressor of disease-and injury-induced proinflammatory cytokine overproduction” NCT05020535 ↗ |
| Modality | Small molecule | “MW01-6-189WH (MW189) is a novel central nervous system-penetrant small-molecule drug candidate” PMID 32255549 ↗ Apr 2020 |
| Route | Intravenous | “Single iv dose of TT301” NCT01357421 ↗ |